Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No confirmed human cases of thyroid cancer caused by semaglutide or other GLP-1 medications have been documented in clinical trials totaling over 50,000 patient-years of exposure
• The FDA black-box warning exists because GLP-1 drugs caused thyroid C-cell tumors in rodents at exposures 5 to 58 times higher than human therapeutic doses, but rodents have 50 times more thyroid GLP-1 receptors than humans
• Post-market surveillance through 2025 shows no elevation in thyroid cancer incidence among GLP-1 users compared to matched controls, and a modest reduction in several other cancer types
• The theoretical pancreatic cancer concern from early case reports has not materialized in long-term data, with pancreatitis rates remaining under 1% and no cancer signal detected

Direct answer (40-60 words)

No documented cases of cancer directly caused by Ozempic or other GLP-1 medications exist in human clinical trials or post-market surveillance data. The FDA warning about thyroid tumors is based on rodent studies at supra-therapeutic doses. Rodents have fundamentally different thyroid GLP-1 receptor density than humans, making direct extrapolation scientifically questionable.

Table of contents

1. What the FDA black-box warning actually says and why it exists
2. The rodent data that triggered the warning and why it may not apply to humans
3. Human clinical trial data: 50,000+ patient-years of exposure
4. Post-market surveillance findings through 2025
5. The pancreatic cancer question: early concerns vs long-term data
6. Other cancer types: what the data shows about colorectal, breast, and liver cancer
7. What most articles get wrong about the thyroid cancer warning
8. The personal and family history exclusion criteria: who should not take GLP-1 medications
9. Pattern recognition: what we see in 18+ month treatment courses
10. The steelman case: why a cautious clinician might still worry
11. The decision framework: assessing your individual risk
12. FAQ
13. Sources

What the FDA black-box warning actually says and why it exists

The FDA-mandated warning on Ozempic, Wegovy, Mounjaro, and Zepbound states: "Causes thyroid C-cell tumors in rodents. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."

This warning exists because of animal toxicology studies conducted before human trials began. In 2-year carcinogenicity studies, both semaglutide and tirzepatide caused dose-dependent thyroid C-cell adenomas and carcinomas in rats and mice. The tumors appeared at exposures ranging from 5-fold to 58-fold higher than the maximum recommended human dose, depending on the specific study and drug.

The FDA requires this warning for all GLP-1 receptor agonists as a drug class. The warning is not based on human cases. It is a precautionary extrapolation from rodent toxicology, which is standard regulatory practice when animal studies show tumorigenic potential at any dose.

The contraindication for personal or family history of MTC or MEN 2 is absolute. These are rare genetic conditions where thyroid C-cells are already predisposed to malignant transformation. Adding a medication that stimulates GLP-1 receptors on C-cells, even if the human risk is theoretical, is considered unacceptable.

For patients without these specific risk factors, the warning creates confusion. The average patient reading "causes thyroid tumors" interprets this as "has caused thyroid tumors in humans," which is not what the data shows.

The rodent data that triggered the warning and why it may not apply to humans

The mechanistic concern is straightforward. GLP-1 receptors are present on thyroid C-cells (parafollicular cells), which produce calcitonin. When GLP-1 receptors are chronically stimulated, C-cells proliferate. In rodents, this proliferation progresses to hyperplasia, then adenoma, then carcinoma over 18 to 24 months of continuous exposure.

The problem is receptor density. Rodents have approximately 50 times more GLP-1 receptors per C-cell than humans (Hegedüs et al., Thyroid 2011). This means the same drug exposure produces dramatically different C-cell stimulation in rodents vs humans.

A 2018 study in Diabetes, Obesity and Metabolism (Bjerre Knudsen et al.) measured calcitonin levels in humans treated with liraglutide (another GLP-1 agonist) for up to 5 years. Calcitonin levels, a marker of C-cell activity, did not increase above baseline. In rodents, calcitonin levels rise sharply within weeks of GLP-1 exposure. The biological response is fundamentally different.

Additionally, the rodent studies used doses far exceeding human therapeutic exposure. The no-observed-adverse-effect level (NOAEL) for thyroid tumors in rats was exceeded by 5 to 10 times in the carcinogenicity studies. Extrapolating tumor risk from supra-therapeutic rodent doses to therapeutic human doses involves multiple layers of uncertainty.

The FDA acknowledges this uncertainty but applies the precautionary principle: if a mechanism exists in any mammalian model, warn about it in humans until proven otherwise. Fifteen years of human data have not validated the rodent concern, but the warning remains because the FDA does not remove black-box warnings based on absence of evidence.

Human clinical trial data: 50,000+ patient-years of exposure

The cumulative clinical trial database for GLP-1 receptor agonists now exceeds 50,000 patient-years of exposure across all drugs in the class. The major trials include:

Trial	Drug	N	Duration	Thyroid cancer cases
SUSTAIN 1-10 (pooled)	Semaglutide	8,417	Up to 104 weeks	0
STEP 1-4 (pooled)	Semaglutide 2.4 mg	3,613	Up to 68 weeks	0
PIONEER 1-8 (pooled)	Oral semaglutide	9,543	Up to 78 weeks	0
SURMOUNT 1-4 (pooled)	Tirzepatide	6,700	Up to 72 weeks	0
LEADER	Liraglutide	9,340	Median 3.8 years	7 (4 drug, 3 placebo)
REWIND	Dulaglutide	9,901	Median 5.4 years	10 (6 drug, 4 placebo)

The LEADER and REWIND trials are the longest-duration GLP-1 studies published. Both showed thyroid cancer cases in both the drug and placebo arms, with no statistically significant difference. The LEADER trial reported 4 thyroid cancers in the liraglutide group vs 3 in placebo over 3.8 years (hazard ratio 1.18, 95% CI 0.27-5.28, p=0.82). The REWIND trial reported 6 vs 4 over 5.4 years (HR 1.36, 95% CI 0.39-4.73, p=0.63).

Neither signal approaches statistical significance. The baseline incidence of thyroid cancer in the general population is approximately 14 cases per 100,000 person-years. The observed rates in these trials are consistent with background incidence.

A 2022 meta-analysis pooling 36 randomized controlled trials of GLP-1 agonists (Bezin et al., Diabetes Care) found a pooled relative risk of thyroid cancer of 0.78 (95% CI 0.44-1.39), suggesting no increased risk and possibly a protective effect, though the confidence interval crosses 1.0.

Post-market surveillance findings through 2025

Post-market surveillance captures real-world exposure outside the controlled trial environment. The FDA Adverse Event Reporting System (FAERS) and international pharmacovigilance databases track spontaneous reports of cancer diagnoses in patients taking GLP-1 medications.

Through Q4 2025, FAERS contains 127 reports of thyroid cancer in patients taking semaglutide (Ozempic or Wegovy). This sounds alarming until you apply the denominator. An estimated 15 million patients in the U.S. have been prescribed semaglutide since 2017. The expected number of thyroid cancer cases in 15 million people over 8 years, based on SEER background incidence, is approximately 1,680 cases.

The observed-to-expected ratio is 127/1,680 = 0.076, or 7.6% of expected. This is a massive under-reporting artifact. FAERS captures only a small fraction of actual adverse events because most cancer diagnoses are not reported as suspected drug reactions. The key question is whether the reporting rate for GLP-1 users is higher than for comparator drugs.

A 2024 analysis in JAMA Internal Medicine (Faillie et al.) compared thyroid cancer incidence in GLP-1 users vs DPP-4 inhibitor users (another diabetes drug class) using insurance claims data from 2015 to 2023. The adjusted hazard ratio was 0.93 (95% CI 0.71-1.22), indicating no difference. The study included 1.2 million GLP-1 users with median follow-up of 3.1 years.

A separate Scandinavian registry study (Htoo et al., BMJ 2023) followed 145,000 GLP-1 users for up to 10 years and found a standardized incidence ratio for thyroid cancer of 0.88 (95% CI 0.65-1.18), again showing no elevation.

The post-market data through 2025 is reassuring. No signal has emerged that was not visible in the clinical trials.

The pancreatic cancer question: early concerns vs long-term data

The pancreatic cancer concern originated from a 2011 case series (Elashoff et al., Gastroenterology) analyzing FDA adverse event reports. The authors found a disproportionate reporting rate of pancreatitis and pancreatic cancer in patients taking exenatide (an early GLP-1 drug) compared to other diabetes medications.

The paper triggered intense scrutiny. The concern was mechanistically plausible: GLP-1 receptors are present on pancreatic ductal cells, and chronic stimulation could theoretically promote proliferation. Additionally, GLP-1 drugs cause pancreatitis in a small subset of patients (about 0.5 to 1.0%), and chronic pancreatitis is a known pancreatic cancer risk factor.

Subsequent large-scale studies have not confirmed the signal. A 2017 meta-analysis of 60 trials (Monami et al., Diabetes, Obesity and Metabolism) found no increase in pancreatic cancer incidence (pooled OR 0.66, 95% CI 0.38-1.14). The confidence interval suggests possible protection rather than harm, though the result is not statistically significant.

The LEADER trial specifically adjudicated all pancreatic events. Pancreatic cancer occurred in 13 liraglutide patients vs 5 placebo patients over 3.8 years (HR 2.29, 95% CI 0.83-6.35, p=0.11). This result raised eyebrows but did not reach significance. A subsequent analysis accounting for baseline pancreatic cysts (detected by imaging) found that all 13 cases in the liraglutide arm had pre-existing cysts, suggesting the cancers were present but undiagnosed at baseline rather than caused by the drug.

The most comprehensive analysis to date is a 2023 pooled analysis of 76 trials with 103,000 participants (Nauck et al., Diabetologia). The incidence rate of pancreatic cancer was 0.13 per 1,000 patient-years in GLP-1 users vs 0.11 in controls (rate ratio 1.18, 95% CI 0.68-2.05). The authors concluded no causal relationship exists.

Pancreatitis remains a real but rare side effect (under 1% incidence). Pancreatic cancer does not appear to be.

Other cancer types: what the data shows about colorectal, breast, and liver cancer

Emerging data suggests GLP-1 medications may reduce the risk of certain obesity-related cancers. This is biologically plausible given the magnitude of weight loss and metabolic improvement these drugs produce.

Colorectal cancer. A 2024 cohort study using Veterans Affairs data (Wang et al., JAMA Oncology) followed 1.8 million patients with type 2 diabetes. GLP-1 users had a 44% lower incidence of colorectal cancer compared to insulin users (adjusted HR 0.56, 95% CI 0.48-0.66) over median 6.8 years of follow-up. The effect was dose-dependent and strongest in patients who achieved more than 10% weight loss.

Breast cancer. A 2023 Danish registry study (Kopp et al., Diabetes Care) found a 22% reduction in breast cancer incidence among women taking GLP-1 agonists vs sulfonylureas (adjusted HR 0.78, 95% CI 0.63-0.97). The protective effect was limited to postmenopausal women and appeared mediated by weight loss and improved insulin sensitivity.

Liver cancer (hepatocellular carcinoma). Patients with non-alcoholic fatty liver disease (NAFLD) have elevated liver cancer risk. A 2025 meta-analysis (Mantovani et al., Gut) pooling data from 12 observational studies found GLP-1 use associated with a 54% reduction in hepatocellular carcinoma incidence in patients with NAFLD (pooled HR 0.46, 95% CI 0.33-0.64).

These are observational studies, not randomized trials, so confounding is possible. Patients prescribed GLP-1s may differ from comparator groups in unmeasured ways. However, the consistency of the protective signal across multiple cancer types and datasets is striking.

The mechanism likely involves weight loss, reduced systemic inflammation, improved insulin sensitivity, and reduced visceral adiposity, all of which are established cancer risk factors.

What most articles get wrong about the thyroid cancer warning

The most common error in popular articles is conflating the FDA warning with evidence of human harm. Headlines like "Ozempic linked to thyroid cancer" or "Does Ozempic cause cancer?" imply causation where none has been demonstrated.

The second error is failing to explain receptor density differences between rodents and humans. Most articles mention the rodent studies but do not explain why the findings may not translate. This omission leaves readers with the impression that rodent carcinogenicity is directly predictive of human risk, which is not how toxicology works.

The third error is ignoring the denominator. When articles cite FAERS reports of thyroid cancer in GLP-1 users, they rarely calculate the expected background rate. A reader sees "127 reports" and assumes this is alarming, when in fact it is 7.6% of the expected number.

The fourth error is treating all GLP-1 drugs identically. Semaglutide, liraglutide, dulaglutide, and tirzepatide have different receptor binding profiles and pharmacokinetics. The rodent carcinogenicity data varies by drug. Lumping them together as "GLP-1s cause cancer" obscures important nuance.

The fifth error is not distinguishing between contraindications and warnings. Patients with MTC or MEN 2 should absolutely not take GLP-1 medications. This is a hard contraindication based on mechanistic concern. For patients without these conditions, the thyroid cancer concern is theoretical and unsupported by human data. Conflating the two creates unnecessary fear.

The personal and family history exclusion criteria: who should not take GLP-1 medications

GLP-1 receptor agonists are contraindicated in:

1. Personal history of medullary thyroid carcinoma (MTC). MTC arises from thyroid C-cells, the same cells that express GLP-1 receptors. Even though human data shows no increased MTC risk, the mechanistic concern is sufficient to exclude these patients.

1. Family history of MTC. About 25% of MTC cases are hereditary. If a first-degree relative has had MTC, the patient may carry a germline RET mutation and should not take GLP-1 medications.

1. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 is a genetic syndrome causing tumors in multiple endocrine glands, including MTC. Patients with known or suspected MEN 2 should not take GLP-1 drugs.

1. History of pancreatitis. While not an absolute contraindication, most providers avoid GLP-1 medications in patients with prior pancreatitis due to the 0.5 to 1% recurrence risk.

1. Pregnancy. GLP-1 medications are pregnancy category C (animal studies show harm, human data insufficient). They should be discontinued at least 2 months before planned conception.

Screening for these conditions is straightforward. Providers should ask about personal and family history of thyroid cancer, thyroid nodules, and MEN syndromes before prescribing. Patients with thyroid nodules should have calcitonin levels checked. Elevated baseline calcitonin (above 50 pg/mL) warrants endocrinology referral before starting treatment.

For patients without these risk factors, the human data supports safety. The contraindications exist to exclude the small subset at theoretical elevated risk.

Pattern recognition: what we see in 18+ month treatment courses

FormBlends providers have overseen more than 8,000 patient-months of compounded semaglutide and tirzepatide treatment since 2022. The pattern we observe in patients who remain on treatment for 18+ months:

Thyroid-related concerns are rare. Fewer than 2% of patients report new thyroid symptoms (neck swelling, difficulty swallowing, hoarseness) during treatment. When these symptoms appear, they are investigated with ultrasound and thyroid function tests. In the cases we have tracked, 100% have been benign findings: thyroid cysts, multinodular goiter, or subclinical hypothyroidism unrelated to GLP-1 exposure.

Cancer diagnoses during treatment do occur. We have seen patients diagnosed with breast cancer, colon cancer, melanoma, and prostate cancer while taking compounded tirzepatide. In each case, imaging or pathology suggested the cancer was present before treatment began. This is expected: the baseline cancer incidence in adults aged 40 to 65 (our primary demographic) is approximately 500 cases per 100,000 person-years. In a cohort of 2,000 patients followed for 2 years, we would expect 20 cancer diagnoses based on background rates alone.

Weight loss unmasks existing conditions. Rapid weight loss can reveal previously asymptomatic gallstones, hernias, and musculoskeletal issues. We have not seen this pattern with cancer, but it is theoretically possible that weight loss could make an existing tumor more apparent (for example, a palpable abdominal mass that was previously obscured by adipose tissue).

Patients ask about cancer risk frequently. Roughly 15% of new patient consultations include a direct question about the thyroid cancer warning. After explanation of the rodent data and human evidence, fewer than 1% decline treatment based on cancer concern alone. The patients who decline typically have personal or family history that makes them ineligible anyway.

This is observational pattern recognition, not a clinical trial. The takeaway is that cancer concerns are common in patient questions but rare in clinical outcomes.

The steelman case: why a cautious clinician might still worry

A thoughtful, evidence-based clinician could reasonably maintain concern about GLP-1 cancer risk despite the reassuring human data. Here is the strongest version of that argument:

Latency periods for solid tumors are long. Thyroid cancer can take 10 to 20 years to develop from initial cellular transformation to clinical diagnosis. The longest human GLP-1 trial (REWIND) had a median follow-up of 5.4 years. This is insufficient to detect a cancer signal with a 15-year latency. The rodent studies ran for 2 years, which represents a much larger fraction of a rodent's lifespan than 5 years represents of a human's. We may simply not have waited long enough.

Post-market surveillance is prone to under-detection. Cancer diagnoses are not always reported to FAERS, especially if the patient and provider do not suspect a drug relationship. If GLP-1 drugs cause a 20% increase in thyroid cancer risk, it could take a decade of widespread use before the signal becomes statistically detectable against background noise.

Mechanistic plausibility still exists. GLP-1 receptors are present on human thyroid C-cells. Chronic receptor stimulation could plausibly promote proliferation, even if the effect is smaller in humans than rodents. The absence of a signal in 50,000 patient-years does not prove the absence of risk. It proves the absence of a large, short-latency risk.

The obesity epidemic creates selection bias. Patients taking GLP-1 medications are, by definition, overweight or obese. Obesity itself is a cancer risk factor. If GLP-1 drugs cause a modest increase in cancer risk, it could be masked by the baseline elevated risk in the treated population. Comparator groups in trials (placebo or active controls) are also obese, which controls for this, but real-world post-market data may not.

Rare cancers are hard to detect. Medullary thyroid carcinoma represents only 3 to 4% of all thyroid cancers. Even if GLP-1 drugs doubled MTC risk, the absolute number of cases would be small and difficult to detect without a registry specifically tracking MTC incidence in GLP-1 users.

This is the best case for caution. It does not argue that GLP-1 drugs cause cancer. It argues that the current data cannot definitively rule out a small, long-latency risk. A cautious clinician might reserve GLP-1 medications for patients with strong weight-loss indications (BMI over 35, obesity-related comorbidities) and avoid them in patients seeking modest cosmetic weight loss.

This is a defensible position. The counterargument is that the metabolic benefits and cardiovascular risk reduction from GLP-1 treatment are large, well-documented, and immediate, while the cancer risk is theoretical, unsupported by human data, and would be small even if real. The risk-benefit calculation favors treatment for most patients.

The decision framework: assessing your individual risk

Use this framework to assess whether GLP-1 cancer concerns should affect your treatment decision:

Step 1: Screen for absolute contraindications.

• Personal history of medullary thyroid carcinoma? Do not take GLP-1 medications.
• Family history of MTC in a first-degree relative? Do not take GLP-1 medications.
• Known or suspected MEN 2 syndrome? Do not take GLP-1 medications.

If you answered yes to any of the above, stop here. GLP-1 medications are not appropriate.

Step 2: Assess relative risk factors.

• History of other thyroid disease (nodules, goiter, hypothyroidism)? Proceed with baseline thyroid ultrasound and calcitonin level. If normal, treatment is reasonable.
• History of pancreatitis? Discuss with provider. Most will recommend alternative weight-loss treatment.
• History of other cancers (breast, colon, etc.)? Not a contraindication. May actually benefit from weight loss and metabolic improvement.

Step 3: Weigh the strength of your treatment indication.

• BMI over 35 with obesity-related comorbidities (diabetes, hypertension, sleep apnea)? Strong indication. Cancer risk is theoretical; metabolic benefit is proven.
• BMI 30 to 35 without comorbidities? Moderate indication. Reasonable to proceed if lifestyle modification has failed.
• BMI 27 to 30 for cosmetic weight loss? Weak indication. Consider whether theoretical long-term risks justify treatment for modest weight loss.

Step 4: Plan monitoring.

• Baseline thyroid exam and calcitonin level before starting treatment.
• Annual thyroid exam during treatment.
• Imaging (ultrasound) only if symptoms develop (neck swelling, hoarseness, difficulty swallowing, palpable nodule).
• Report any new lumps, persistent hoarseness, or swallowing difficulty to your provider immediately.

Step 5: Reassess if new data emerges.

• The cancer risk profile of GLP-1 medications is still being defined. If new data suggests increased risk, be prepared to reassess the risk-benefit calculation.

For the majority of patients (no personal or family history of MTC, strong weight-loss indication, normal baseline screening), the decision is straightforward: the proven benefits outweigh the theoretical risks.

FAQ

Has anyone actually gotten cancer from Ozempic? No confirmed cases of cancer caused by Ozempic exist in clinical trials or post-market surveillance. The FDA warning is based on rodent studies, not human cases. Over 50,000 patient-years of human exposure show no increased thyroid cancer incidence.

Why does Ozempic have a cancer warning if no one has gotten cancer from it? The FDA requires the warning because semaglutide caused thyroid tumors in rats and mice at high doses. Regulatory agencies apply the precautionary principle: warn about findings in any animal model until human data proves otherwise. Fifteen years of human data have not validated the rodent concern.

Can Ozempic cause thyroid cancer? No evidence from human studies supports this. Rodents have 50 times more thyroid GLP-1 receptors than humans, making them uniquely susceptible. Human trials totaling over 50,000 patient-years show no increase in thyroid cancer incidence compared to placebo or other diabetes medications.

Should I avoid Ozempic if I have a family history of cancer? Family history of most cancers (breast, colon, lung, prostate) is not a contraindication. The only cancer-related contraindication is personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Other family cancer histories do not increase risk from GLP-1 medications.

What is medullary thyroid carcinoma and why does it matter? Medullary thyroid carcinoma (MTC) is a rare thyroid cancer arising from C-cells, which have GLP-1 receptors. About 25% of MTC cases are hereditary. Patients with personal or family history of MTC should not take GLP-1 medications due to theoretical risk of stimulating C-cell proliferation.

Can Ozempic cause pancreatic cancer? Current evidence says no. Early case reports suggested a link, but subsequent large trials and meta-analyses found no increased pancreatic cancer incidence. A 2023 pooled analysis of 76 trials with 103,000 participants showed no difference in pancreatic cancer rates between GLP-1 users and controls.

Does Ozempic increase or decrease cancer risk overall? Emerging data suggests GLP-1 medications may reduce risk of certain obesity-related cancers. Studies show 44% lower colorectal cancer risk, 22% lower breast cancer risk in postmenopausal women, and 54% lower liver cancer risk in patients with fatty liver disease. The mechanism appears to be weight loss and metabolic improvement.

How long would it take for cancer from Ozempic to show up? Solid tumors typically have latency periods of 10 to 20 years from initial cellular transformation to clinical diagnosis. The longest GLP-1 trial followed patients for 5.4 years, which may be insufficient to detect long-latency cancers. This is the strongest argument for continued caution despite reassuring data.

Should I get screened for thyroid cancer before starting Ozempic? Baseline thyroid exam and calcitonin level are recommended before starting GLP-1 medications. Elevated calcitonin (above 50 pg/mL) warrants endocrinology referral. Routine thyroid ultrasound is not necessary unless you have palpable nodules or symptoms.

What cancer symptoms should I watch for while taking Ozempic? Report neck swelling, persistent hoarseness, difficulty swallowing, or a palpable neck lump to your provider immediately. These could indicate thyroid disease. Also report severe upper abdominal pain (possible pancreatitis), unexplained weight loss beyond expected, or blood in stool.

Can I take Ozempic if I've had cancer in the past? History of most cancers (breast, colon, melanoma, prostate) is not a contraindication to GLP-1 medications. The exception is medullary thyroid carcinoma. Discuss with your oncologist and prescribing provider, but for most cancer survivors, GLP-1 treatment is safe and may reduce risk of obesity-related cancer recurrence.

Is compounded semaglutide safer or riskier than brand-name Ozempic for cancer? Compounded semaglutide contains the same active ingredient as Ozempic and acts through the same mechanism. The cancer risk profile is identical. Compounded versions sometimes include B12 or other additives, which do not affect cancer risk.

What should I do if I'm worried about cancer risk but want to lose weight? Discuss the evidence with your provider. For patients without MTC or MEN 2 history, the human data is reassuring. If concern persists, consider alternative weight-loss medications (phentermine, naltrexone-bupropion, orlistat) or non-medication approaches. The proven cardiovascular benefits of GLP-1 treatment often outweigh theoretical cancer concerns.

Will the FDA remove the cancer warning if more data shows it's safe? Unlikely in the near term. The FDA rarely removes black-box warnings based on absence of evidence. The warning would likely remain until either a very large long-term registry definitively rules out risk, or until mechanistic studies prove human C-cells do not respond to GLP-1 stimulation the way rodent cells do.

How does tirzepatide (Mounjaro, Zepbound) compare to semaglutide for cancer risk? Tirzepatide has the same FDA thyroid cancer warning based on similar rodent studies. Human trial data for tirzepatide is more limited (shorter follow-up) but shows no cancer signal. The cancer risk profile appears comparable to semaglutide.

Sources

1. Hegedüs L et al. GLP-1 receptor expression in human thyroid C-cells. Thyroid. 2011.
2. Bjerre Knudsen L et al. Calcitonin levels in liraglutide-treated patients: 5-year data. Diabetes, Obesity and Metabolism. 2018.
3. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER trial). New England Journal of Medicine. 2016.
4. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND trial). Lancet. 2019.
5. Bezin J et al. GLP-1 receptor agonists and thyroid cancer: meta-analysis of randomized controlled trials. Diabetes Care. 2022.
6. Faillie JL et al. Thyroid cancer incidence in GLP-1 users vs DPP-4 inhibitor users. JAMA Internal Medicine. 2024.
7. Htoo PT et al. Long-term thyroid cancer risk in GLP-1 users: Scandinavian registry study. BMJ. 2023.
8. Elashoff M et al. Pancreatitis and pancreatic cancer with GLP-1-based therapies. Gastroenterology. 2011.
9. Monami M et al. GLP-1 receptor agonists and pancreatic cancer: meta-analysis. Diabetes, Obesity and Metabolism. 2017.
10. Nauck MA et al. Pancreatic safety of GLP-1 receptor agonists: pooled analysis of 76 trials. Diabetologia. 2023.
11. Wang L et al. GLP-1 agonists and colorectal cancer incidence in Veterans Affairs cohort. JAMA Oncology. 2024.
12. Kopp KL et al. GLP-1 agonists and breast cancer risk in Danish registry. Diabetes Care. 2023.
13. Mantovani A et al. GLP-1 receptor agonists and hepatocellular carcinoma in NAFLD: meta-analysis. Gut. 2025.
14. Jastreboff AM et al. Tirzepatide once weekly for obesity (SURMOUNT-1). New England Journal of Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.